Most Read Articles

The FDA has licensed 2026-2027 formulas of the mRNA COVID-19 vaccines Comirnaty, Spikevax, and mNEXSPIKE and the adjuvanted protein subunit COVID-19 vaccine Nuvaxovid.

Influenza is typically a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1). Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated with influenza illness. Annual vaccination should be offered to all persons ≥6 months old as long as influenza viruses are circulating in the community.

The rapid-acting inhaled human insulin Afrezza (MannKind), which was approved in 2014 for treatment of type 1 or type 2 diabetes in adults, has now been approved by the FDA for use in children ≥6 years old.

Annual influenza vaccination is recommended for all persons ≥6 months old without a contraindication. Influenza vaccines available this season in the US are listed in Table 3.

View the Comparison Chart: Antiviral Drugs for Seasonal Influenza

The FDA has approved tezepelumab (Tezspire – Amgen/AstraZeneca), a subcutaneously administered thymic stromal lymphopoietin (TSLP) blocker, for add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in patients ≥12 years old. It is the first TSLP blocker to be approved for this indication. Tezepelumab was approved for add-on maintenance treatment of severe asthma in 2021.

Camizestrant (Etcamah – AstraZeneca), an oral estrogen receptor antagonist, has received accelerated approval from the FDA for use in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have ESR1 mutations that were detected in circulating tumor DNA (ctDNA) during treatment with an aromatase inhibitor and a CDK 4/6 inhibitor.

Iberdomide (Zenbexus – BMS), an oral first-in-class cereblon-modulating protein degrader, has received accelerated approval from the FDA for use in combination with the CD38-directed cytolytic antibody daratumumab (Darzalex Faspro) and dexamethasone for treatment of multiple myeloma in adults who received at least one prior line of therapy, including a proteasome inhibitor (e.g., bortezomib) and an immunomodulatory drug. The drug was approved based on a surrogate endpoint of minimal residual disease-negative complete response.

Zidesamtinib (Jideytro – GSK), an oral kinase inhibitor, has been approved by the FDA for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults who received at least one prior ROS1 kinase inhibitor. It is the fifth oral kinase inhibitor to be approved in the US for treatment of ROS1-positive NSCLC; crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) were approved earlier.

Tavapadon (Juvmo – Abbvie), an oral nonergot partial dopamine agonist, has been approved by the FDA for treatment of Parkinson's disease (PD).